Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2002 Oct;78(924):599–606. doi: 10.1136/pmj.78.924.599

Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge

Y Ioannou 1, D Isenberg 1
PMCID: PMC1742538  PMID: 12415083

Full Text

The Full Text of this article is available as a PDF (280.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bansal V. K., Beto J. A. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis. 1997 Feb;29(2):193–199. doi: 10.1016/s0272-6386(97)90029-9. [DOI] [PubMed] [Google Scholar]
  2. Boletis J. N., Ioannidis J. P., Boki K. A., Moutsopoulos H. M. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet. 1999 Aug 14;354(9178):569–570. doi: 10.1016/S0140-6736(99)01575-5. [DOI] [PubMed] [Google Scholar]
  3. Boumpas D. T., Austin H. A., 3rd, Vaughn E. M., Klippel J. H., Steinberg A. D., Yarboro C. H., Balow J. E. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992 Sep 26;340(8822):741–745. doi: 10.1016/0140-6736(92)92292-n. [DOI] [PubMed] [Google Scholar]
  4. Caccavo D., Laganà B., Mitterhofer A. P., Ferri G. M., Afeltra A., Amoroso A., Bonomo L. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum. 1997 Jan;40(1):27–35. doi: 10.1002/art.1780400106. [DOI] [PubMed] [Google Scholar]
  5. Carneiro J. R., Sato E. I. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999 Jun;26(6):1275–1279. [PubMed] [Google Scholar]
  6. Chan T. M., Li F. K., Tang C. S., Wong R. W., Fang G. X., Ji Y. L., Lau C. S., Wong A. K., Tong M. K., Chan K. W. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000 Oct 19;343(16):1156–1162. doi: 10.1056/NEJM200010193431604. [DOI] [PubMed] [Google Scholar]
  7. Cohen S., Levy R. M., Keller M., Boling E., Emkey R. D., Greenwald M., Zizic T. M., Wallach S., Sewell K. L., Lukert B. P. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 1999 Nov;42(11):2309–2318. doi: 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  8. Gladman D. D., Urowitz M. B. The SLICC/ACR damage index: progress report and experience in the field. Lupus. 1999;8(8):632–637. doi: 10.1191/096120399680411335. [DOI] [PubMed] [Google Scholar]
  9. HOLBOROW E. J., WEIR D. M., JOHNSON G. D. A serum factor in lupus erythematosus with affinity for tissue nuclei. Br Med J. 1957 Sep 28;2(5047):732–734. doi: 10.1136/bmj.2.5047.732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hakim A. J., Machin S. J., Isenberg D. A. Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy. Semin Arthritis Rheum. 1998 Aug;28(1):20–25. doi: 10.1016/s0049-0172(98)80024-3. [DOI] [PubMed] [Google Scholar]
  11. Hodis H. N., Quismorio F. P., Jr, Wickham E., Blankenhorn D. H. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol. 1993 Apr;20(4):661–665. [PubMed] [Google Scholar]
  12. Illei G. G., Austin H. A., Crane M., Collins L., Gourley M. F., Yarboro C. H., Vaughan E. M., Kuroiwa T., Danning C. L., Steinberg A. D. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 Aug 21;135(4):248–257. doi: 10.7326/0003-4819-135-4-200108210-00009. [DOI] [PubMed] [Google Scholar]
  13. Ioannou Y., Isenberg D. A. Immunisation of patients with systemic lupus erythematosus: the current state of play. Lupus. 1999;8(7):497–501. doi: 10.1191/096120399678840855. [DOI] [PubMed] [Google Scholar]
  14. Isenberg D. A., Gladman D. The Systemic Lupus International Collaborating Clinics Group--origins and outcomes. Lupus. 2001;10(5):375–377. doi: 10.1191/096120301676101377. [DOI] [PubMed] [Google Scholar]
  15. Isenberg D. A., Snaith M. L., Morrow W. J., Al-Khader A. A., Cohen S. L., Fisher C., Mowbray J. Cyclosporin A for the treatment of systemic lupus erythematosus. Int J Immunopharmacol. 1981;3(2):163–169. doi: 10.1016/0192-0561(81)90007-2. [DOI] [PubMed] [Google Scholar]
  16. Levy G. D., Munz S. J., Paschal J., Cohen H. B., Pince K. J., Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997 Aug;40(8):1482–1486. doi: 10.1002/art.1780400817. [DOI] [PubMed] [Google Scholar]
  17. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., Antoni C., Leeb B., Elliott M. J., Woody J. N. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552–1563. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  18. Mok C. C., Wong R. W. Pregnancy in systemic lupus erythematosus. Postgrad Med J. 2001 Mar;77(905):157–165. doi: 10.1136/pmj.77.905.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Naughton M. A., Battaglia E., O'Brien S., Walport M. J., Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford) 1999 Jul;38(7):640–644. doi: 10.1093/rheumatology/38.7.640. [DOI] [PubMed] [Google Scholar]
  20. Rahman P., Humphrey-Murto S., Gladman D. D., Urowitz M. B. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol. 1998 Feb;25(2):243–246. [PubMed] [Google Scholar]
  21. Ramsey-Goldman R., Dunn J. E., Huang C. F., Dunlop D., Rairie J. E., Fitzgerald S., Manzi S. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 1999 May;42(5):882–890. doi: 10.1002/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  22. Reid D. M., Hughes R. A., Laan R. F., Sacco-Gibson N. A., Wenderoth D. H., Adami S., Eusebio R. A., Devogelaer J. P. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000 Jun;15(6):1006–1013. doi: 10.1359/jbmr.2000.15.6.1006. [DOI] [PubMed] [Google Scholar]
  23. Salmon J. E., Roman M. J. Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol. 2001 Sep;13(5):341–344. doi: 10.1097/00002281-200109000-00001. [DOI] [PubMed] [Google Scholar]
  24. Sen D., Keen R. W. Osteoporosis in systemic lupus erythematosus: prevention and treatment. Lupus. 2001;10(3):227–232. doi: 10.1191/096120301671413439. [DOI] [PubMed] [Google Scholar]
  25. Shipley M., Silman A. Should patients on hydroxychloroquine have their eyes examined regularly? Br J Rheumatol. 1997 May;36(5):514–515. doi: 10.1093/rheumatology/36.5.514. [DOI] [PubMed] [Google Scholar]
  26. Stone J. H., Amend W. J., Criswell L. A. Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls. Arthritis Rheum. 1998 Aug;41(8):1438–1445. doi: 10.1002/1529-0131(199808)41:8<1438::AID-ART14>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  27. Stone J. H., Millward C. L., Olson J. L., Amend W. J., Criswell L. A. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era. Arthritis Rheum. 1998 Apr;41(4):678–686. doi: 10.1002/1529-0131(199804)41:4<678::AID-ART15>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  28. Traynor A. E., Schroeder J., Rosa R. M., Cheng D., Stefka J., Mujais S., Baker S., Burt R. K. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet. 2000 Aug 26;356(9231):701–707. doi: 10.1016/S0140-6736(00)02627-1. [DOI] [PubMed] [Google Scholar]
  29. Walton A. J., Snaith M. L., Locniskar M., Cumberland A. G., Morrow W. J., Isenberg D. A. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis. 1991 Jul;50(7):463–466. doi: 10.1136/ard.50.7.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Weinshilboum R. M., Sladek S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980 Sep;32(5):651–662. [PMC free article] [PubMed] [Google Scholar]
  31. Yates C. R., Krynetski E. Y., Loennechen T., Fessing M. Y., Tai H. L., Pui C. H., Relling M. V., Evans W. E. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997 Apr 15;126(8):608–614. doi: 10.7326/0003-4819-126-8-199704150-00003. [DOI] [PubMed] [Google Scholar]
  32. Zonana-Nacach A., Barr S. G., Magder L. S., Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000 Aug;43(8):1801–1808. doi: 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES